SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP

SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP

TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG

Canada (ACCESSWIRE) Sunshine Biopharma Inc. (OTC

Markets: SBFM ), a pharmaceutical company focused on

the research, development and commercialization of oncology and

antiviral drugs today announced that it has entered into an

Agreement with the University of Georgia for the purposes of

working together to advance the development of Sunshine

Biopharma's recently announced Anti-Coronavirus lead

compound, SBFM-PL4. The goal of this cutting-edge collaboration is

to develop SBFM-PL4, a protease inhibitor, as a treatment for

Coronavirus infections. This new treatment is based on the

technology described in Sunshine Biopharma's recently filed

patent application covering small molecules which can be used to

treat Coronavirus infections. Sunshine's SBFM-PL4, will be

put through a series of in

vitro tests to evaluate its specific inhibitory activity

against the SARS-CoV-2 papain-like protease (PLpro), one of two

Coronavirus encoded proteases essential for viral replication.

Following the initial in

vitro studies, SBFM-PL4 will be moved forward to the cell

culture testing stage and assessment in Coronavirus infected mice

before entering human clinical trials.

are delighted to be working with the University of Georgia and Dr.

Scott Pegan and his team of Coronavirus experts who share our

vision of developing a treatment that would make a difference in

the fight against the pandemic, said Dr. Steve Slilaty, CEO

of Sunshine Biopharma.

About Sunshine Biopharma's Coronavirus Treatment

Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the

causative agent of COVID-19, the current ongoing pandemic that has

claimed the lives of over 1,000,000 people worldwide since it first

appeared in December 2019. There are currently no drugs that can

effectively arrest replication of the virus in people who have

contracted the illness. On May 22, 2020, Sunshine Biopharma filed a

provisional patent application for a library of molecules which

were designed to inhibit the Coronavirus proteases, thus shutting

down the ability of the virus to multiply and cause

About the University of Georgia

of its land grant tripartite mission, the University of Georgia is

committed to creating and applying new knowledge for the public

good. UGA's Center for Drug Discovery as well as the Colleges

of Pharmacy are excited to be a part of this ground-breaking

research related to discovery of new treatment options for

COVID-19. Profs. Scott Pegan, and David Crich will be working with

Sunshine Biopharma to spearhead the study of novel therapeutics for

the prevention and spread of COVID-19. This interdisciplinary

effort involves state of the art approaches in chemical synthesis

and drug screening. This continues University of Georgia's

long-standing tradition in translating scientific breakthroughs to

address real world health concerns.

About Sunshine Biopharma

addition, to working on the development of a treatment for

COVID-19, Sunshine Biopharma is engaged in the development

Adva-27a, a unique anticancer compound. Tests conducted to date

have demonstrated the effectiveness of Adva-27a at destroying

Multidrug Resistant Cancer Cells, including Pancreatic Cancer

cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and

Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer

indication are planned to be conducted at McGill University's

Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is

owner of all patents and intellectual property pertaining to

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are

based on current expectations, forecasts, and assumptions that

involve risks as well as uncertainties that could cause actual

outcomes and results to differ materially from those anticipated or

expected, including statements related to the amount and timing of

expected revenues statements related to our financial performance,

expected income, distributions, and future growth for upcoming

quarterly and annual periods. These risks and uncertainties are

further defined in filings and reports by the Company with the U.S.

Securities and Exchange Commission (SEC). Actual results and

the timing of certain events could differ materially from those

projected in or contemplated by the forward-looking statements due

to a number of factors detailed from time to time in our filings

with the SEC. Among other matters, the Company may not be able to

sustain growth or achieve profitability based upon many factors

including but not limited to general stock market conditions.

Reference is hereby made to cautionary statements set forth in the

Company's most recent SEC filings. We have incurred and will

continue to incur significant expenses in our expansion of our

existing as well as new service lines noting there is no assurance

that we will generate enough revenues to offset those costs in both

the near and long term. Additional service offerings may

expose us to additional legal and regulatory costs and unknown

exposure(s) based upon the various geopolitical locations we will

be providing services in, the impact of which cannot be predicted

For Additional Information:

Sunshine Biopharma, Inc.